REGENEUS LTD - ASX Briefs

*Disclaimer

REGENEUS LTD (ASX: RGS)

RGS: Merger with Cambium

REGENEUS LTD

Regeneus Ltd announces a non-binding indicative offer letter to merge with Cambium Medical Technologies, LLC (CMT).
CMT is developing a Phase 3-ready biologic therapeutic, Elate Ocular®, to treat dry eye disease (DED) and has obtained two IND approvals from the FDA for Phase 3 trials.
Elate Ocular could address a large market need, with the current market size for prescription drugs to treat DED in the USA estimated to be over US$2B.

2023-04-28 09:09:00

RGS: Regeneus agrees to settle $2m loan

REGENEUS LTD

Regeneus has reached an agreement to settle a $2 million loan and interest payable to a related entity, Paddington St Finance, in exchange for 700,000 shares in Sangui Bio Pty Ltd and $400,000 cash.
The transfer of the Sangui Bio shares will occur within 5 business days of Regeneus receiving shareholder approval.
Regeneus is also exploring opportunities to dispose of other non-core assets such as donor material to improve its liquidity position.

2023-02-28 09:04:00